Drugs for Relapse Prevention of Alcoholism

  • Rainer Spanagel
  • Karl F. Mann

Part of the Milestones in Drug Therapy MDT book series (MDT)

Table of contents

  1. Front Matter
    Pages I-XII
  2. Griffith Edwards
    Pages 1-11
  3. Rainer Spanagel
    Pages 13-21
  4. Henry R. Kranzler, Howard Tennen
    Pages 23-39
  5. Dieter Ladewig, Ulrich von Bardeleben
    Pages 41-48
  6. Michael S. Cowen
    Pages 49-58
  7. Charles P. O’Brien, Helen M. Pettinati, David W. Oslin
    Pages 59-72
  8. Philippe De Witte, Daniel Bachteler, Rainer Spanagel
    Pages 73-83
  9. Karl F. Mann
    Pages 85-93
  10. Anh Dzung Lê, Douglas R. Funk
    Pages 95-106
  11. Bankole A. Johnson
    Pages 107-116
  12. Petri Hyytiä
    Pages 117-124
  13. John David Sinclair
    Pages 125-134
  14. Friedbert Weiss
    Pages 135-153
  15. Gerhard A. Wiesbeck
    Pages 155-161
  16. Mauro A.M. Carai, Roberta Agabio, Giovanni Addolorato, Gian L. Gessa, Giancarlo Colombo
    Pages 163-170
  17. Giovanni Addolorato, Ludovico Abenavoli, Lorenzo Leggio, Giosuè DeLorenzi, Anna Ferrulli, Fabio Caputo et al.
    Pages 171-180
  18. Mauro A.M. Carai, Carla Lobina, Gian Luigi Gessa, Giancarlo Colombo
    Pages 181-187
  19. Markus Heilig, Todd E. Thiele
    Pages 189-203
  20. Daniel Bachteler, Rainer Spanagel
    Pages 205-216
  21. Rainer Spanagel, Karl F. Mann
    Pages 217-226
  22. Back Matter
    Pages 227-243

About this book


Alcoholism is a pathological behavioural syndrome, characterised by comp- sive alcohol use, craving and relapses, even recurring after many years of abstinence. It is suggested that chronic alcohol abuse leads to persistent changes within several neurochemical pathways in the brain and furthermore that an imprinted drug and addiction memory may scarcely be extinguished. Hence, the question arises as to whether there ought to be a reasonable hope that pharmacological drugs will be developed that interfere with an addiction memory, and as a result, finally lead to a cure? In this book, leading preclinical and clinical experts in the field of alcohol relapse prevention strive to furnish an answer to this question. None of the researchers or clinicians believes in a magic bullet that will be of help to all alcoholic patients in overcoming this disease. However, there is now convi- ing evidence demonstrating that specific subpopulations of alcoholic patients experience satisfactory benefit from currently available treatments. Today we have two medications for relapse prevention on the market – acamprosate and naltrexone. Although, currently, only a minority of alcoholic patients benefit from these medications, the approval of these compounds may be considered a hallmark in the field of psychopharmacology, even comparable to the era when the first antidepressant compounds were introduced. In recent years we have been witnessing an enormous growth in the science and knowledge regarding the field of relapse prevention.


Peptide Systems Treatment Strategies alcoholism cannabinoid clinical application clinical research dopamine neuropharmacology neurotransmitter opioid pharmacology prevention psychopharmacology research

Editors and affiliations

  • Rainer Spanagel
    • 1
  • Karl F. Mann
    • 2
  1. 1.Abteilung für PsychopharmakologieUniversit ät HeidelbergMannheimGermany
  2. 2.Klinik für Abhängiges Verhalten und SuchtmedizinMannheimGermany

Bibliographic information

Industry Sectors
Health & Hospitals
Pharmacology & Toxicology
Consumer Packaged Goods